Related Experiment Video
Updated: Aug 14, 2026

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives
1Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The Netherlands.
Preeclampsia pathogenesis involves endothelial dysfunction. Future research should focus on preventing this dysfunction or mitigating its effects, particularly exploring VLDL/TxPA balance and free radical imbalances for primary prevention strategies.
Area of Science:
- Obstetrics and Gynecology
- Cardiovascular Research
- Pathophysiology
Background:
- Endothelial dysfunction is a central mechanism in preeclampsia development.
- Understanding preeclampsia etiology is crucial for effective prevention and treatment strategies.
Purpose of the Study:
- To review primary prevention strategies for preeclampsia.
- To discuss promising research directions for mitigating endothelial dysfunction in preeclampsia.
Main Methods:
- Review of current hypotheses on preeclampsia etiology.
- Analysis of potential therapeutic targets for primary prevention.
Main Results:
- Current hypotheses include placental ischemia, immune maladaptation, VLDL/TxPA imbalance, and genetic factors.
- Disturbed VLDL (very low density lipoproteins)/TxPA (toxicity preventing activity) balance and free radical/scavenger imbalance are identified as clinically relevant areas for future research.
Conclusions:
- Targeting endothelial dysfunction is key for preeclampsia management.
- Further clinical research should investigate VLDL/TxPA balance and oxidative stress for primary prevention of preeclampsia.
More Related Videos
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
05:31Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Peripheral Artery Disease III: Interprofessional Care